1-4 of 4
YouHong Fan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer

Triparna Sen, Pan Tong, Lixia Diao, Lerong Li, Youhong Fan, Jennifer Hoff, John V. Heymach, Jing Wang, Lauren Averett Byers
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (20): 6239–6253.
https://doi.org/10.1158/1078-0432.CCR-17-1284
Published: 12 October 2017
View article titled, Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
Open the PDF for Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib

Monique B. Nilsson, Uma Giri, Jayanthi Gudikote, Ximing Tang, Wei Lu, Hai Tran, Youhong Fan, Andrew Koo, Lixia Diao, Pan Tong, Jing Wang, Roy Herbst, Bruce E. Johnson, Andy Ryan, Alan Webster, Philip Rowe, Ignacio I. Wistuba, John V. Heymach
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (8): 1940–1950.
https://doi.org/10.1158/1078-0432.CCR-15-1994
Published: 14 April 2016
View article titled, KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib
Open the PDF for KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib in another window
Includes: Supplementary data
Journal Articles

An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2

Robert J.G. Cardnell, Carmen Behrens, Lixia Diao, YouHong Fan, Ximing Tang, Pan Tong, John D. Minna, Gordon B. Mills, John V. Heymach, Ignacio I. Wistuba, Jing Wang, Lauren A. Byers
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (15): 3480–3491.
https://doi.org/10.1158/1078-0432.CCR-14-3286
Published: 02 August 2015
View article titled, An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2
Open the PDF for An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2 in another window
Includes: Supplementary data
Journal Articles

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren Averett Byers, Lixia Diao, Jing Wang, Pierre Saintigny, Luc Girard, Michael Peyton, Li Shen, Youhong Fan, Uma Giri, Praveen K. Tumula, Monique B. Nilsson, Jayanthi Gudikote, Hai Tran, Robert J.G. Cardnell, David J. Bearss, Steven L. Warner, Jason M. Foulks, Steven B. Kanner, Varsha Gandhi, Nancy Krett, Steven T. Rosen, Edward S. Kim, Roy S. Herbst, George R. Blumenschein, J. Jack Lee, Scott M. Lippman, K. Kian Ang, Gordon B. Mills, Waun K. Hong, John N. Weinstein, Ignacio I. Wistuba, Kevin R. Coombes, John D. Minna, John V. Heymach
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 279–290.
https://doi.org/10.1158/1078-0432.CCR-12-1558
Published: 02 January 2013
View article titled, An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Open the PDF for An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance in another window
Includes: Supplementary data